Development of an Improved Bio-Manufacturing Platform for the Production of Glyco

DESCRIPTION (provided by applicant): The protein therapeutic market is valued at 99 billion and is the fastest growing segment of the 600 billion pharmaceutical industry. Nearly half of all approved biopharmaceuticals are post-translationally modified byglycosylation [1]. Glycosylation influences protein solubility, serum half-life, immunogenicity and/or biological activity. Animal cell lines are primarily used for the production of therapeutic glycoproteins, due to their ability to generate products with therapeutically acceptable glycoprofiles. However, animal cell lines have limitations including high production costs, reduced safety, and heterogeneity of glycoforms [2,3]. Glycoform heterogeneity can be found both in the site occupancy of the glycan and the structure of the attached glycan; and is influenced by cell culture parameters such as age, pH, nutrient levels, and temperature [4]. Thus, a major challenge for the production of therapeutic glycoproteins from animal cell lines is glycoprofile